Trial
NCT03042013
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Subjects With NSCLC With an EGFR Activating Mutation
Intervention
ASP8273
Why stopped
Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-11